Insilico Medicine Receives IND Approval from FDA for ISM8969, an AI-empowered Potential Best-in-class NLRP3 Inhibitor (IMAGE)
Caption
- Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA) paves the way for ISM8969 clinical study in the United States. The Phase I clinical trial aims to evaluate safety, tolerability, and pharmacokinetics profiles.
- ISM8969 is a novel oral therapeutic candidate developed through Insilico’s Pharma.AI, with best-in-class potential, unique brain penetrant traits, and favorable druggability profiles demonstrated in preclinical studies.
- Insilico Medicine has entered into a co-development collaboration agreement with Hygtia Therapeutics, with both parties each holding 50% of the global rights and interests to the program. In return, Insilico is eligible to receive up to $66 million in upfront and milestone payments.
Credit
Insilico Medicine
Usage Restrictions
None
License
Original content